Publications by authors named "N I Petruk"
Background: Tumour associated macrophages (TAMs) are important players in breast tumour progression and metastasis. Clinical and preclinical evidence suggests a role for zoledronate (ZOL) in breast cancer metastasis prevention. Further, zoledronate is able to induce inflammatory activation of monocytes and macrophages, which can be favourable in cancer treatments.
View Article and Find Full Text PDFIntroduction: Bisphosphonates (BPs) are bone-protecting osteoclast inhibitors, typically used in the treatment of osteoporosis and skeletal complications of malignancies. When given in the adjuvant setting, these drugs may also prevent relapses and prolong overall survival in early breast cancer (EBC), specifically among postmenopausal patients. Because of these findings, adjuvant nitrogen-containing BPs (N-BPs), such as zoledronate (ZOL), are now the standard of care for high-risk EBC patients, but there are no benefit-associated biomarkers, and the efficacy remains low.
View Article and Find Full Text PDFArticle Synopsis
- CD73 is an enzyme that converts adenosine monophosphate to adenosine, and its high expression in triple-negative breast cancer (TNBC) is linked to worse patient outcomes.
- Researchers tested the effects of inhibiting CD73 using a specific compound and shRNA silencing on TNBC cell behavior in both normal and low-oxygen environments.
- The study found that inhibiting CD73 reduced cancer cell viability, migration, and invasiveness, suggesting that CD73 may aid tumor progression by promoting a transition to a more invasive cell type.
Background: Many malignant tumours have increased TSPO expression, which has been related to a poor prognosis. TSPO-PET tracers have not comprehensively been evaluated in peripherally located tumours. This study aimed to evaluate whether N,N-diethyl-2-(2-(4-([F]fluoro)phenyl)-5,7-dimethylpyrazolo[1,5-a]pyrimidin-3-yl)acetamide ([F]F-DPA) can reflect radiotherapy (RT)-induced changes in TSPO activity in head and neck squamous cell carcinoma (HNSCC).
View Article and Find Full Text PDFPurpose: Fibroblast growth factor receptors (FGFR) and pathways are important players in breast cancer (BC) development. They are commonly altered, and BCs exhibiting FGFR gene amplification are currently being studied for drug development. Here, we aimed to compare the effects of three FGFR inhibitors (FGFRis), i.
View Article and Find Full Text PDF